You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.
Researchers used the system to precisely deplete mRNA transcripts in zebrafish embryos and showed that it can also be used in medaka, killifish, and mouse.
News items for the week of August 3, 2020.
The collaborators will develop methods using Bruker's timsTOF Pro for structural and protein interaction work that the company plans to commercialize.
The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.
Natera previously filed infringement lawsuits against ArcherDx around four other patents related to cell-free DNA detection in oncology.
The company said it broadened the scope of its life science products to include COVID-19 reagents used by manufacturers to develop rapid antigen tests.
Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.
The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.
In Q2 the firm filed for FDA Emergency Use Authorization for its saliva-based Advanta Sx SARS-CoV-2 RT-PCR assay as it continued its pivot to COVID-19 markets.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
The Bay Area DNA synthesis company said it was "not significantly affected" by the COVID-19 pandemic and beat Wall Street revenue estimates.
Although its research test volume decreased significantly because of the COVID-19 pandemic, the company saw revenue growth across both clinical testing and development services.
The San Diego-based genomic analysis firm said the decline in revenues was due to the impact of the COVID-19 pandemic on research customers.
The company's Q2 revenue growth was driven by a 74 percent increase in revenues from the analytical services it provided to the VA MVP program.
The cancer therapy developer has asked a US federal court to declare that its Illuminox platform does not infringe Illumina's trademarks.
Samples collected over time from more than 300 SARS-CoV-2-infected young adults pointed to prolonged viral shedding in symptom-free individuals.
With a new analytical tool, researchers uncovered ancient archaic hominin sequences in the Denisovan genome, along with human introgression into Neanderthals up to 300,000 years ago.
The Beijing-based company, which went public in the US in June to raise $235.0 million, specializes in genomic products and services for cancer.
The companies are validating the Genedrive 96 Sars-CoV-2 kit using saliva samples extracted with Beckman Coulter's RNAdvance viral extraction chemistry
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
The firm will use the proceeds to support commercialization, regulatory, and product development activities, as well as for general working capital purposes.
GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.